Fintel reports that on April 9, 2025, HC Wainwright & Co. downgraded their outlook for Rallybio (NasdaqGS:RLYB) from Buy to ...

Fintel reports that on April 9, 2025, HC Wainwright & Co. initiated coverage of vTv Therapeutics (NasdaqCM:VTVT) with a Buy ...

Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Alnylam ...

H.C. Wainwright analyst Emily Bodnar initiated coverage of vTv Therapeutics (VTVT) with a Buy rating and $36 price target The company’s lead ...

H.C. Wainwright analyst Patrick Trucchio initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $10 price ...

Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks.

H.C. Wainwright analyst Yi Chen initiated coverage of Bionano Genomics (BNGO) with a Buy rating and $10 price target Bionano is a ...

HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of ($0.90) for the quarter, up from their previous estimate of ($1.13).

Fintel reports that on April 7, 2025, HC Wainwright & Co. initiated coverage of Ionis Pharmaceuticals (NasdaqGS:IONS) with a Buy recommendation. As of April 2, 2025, the average one-year price ...

H.C. Wainwright says Novo Nordisk’s (NVO) REDEFINE-2 results reinforce Viking Therapeutics’ (VKTX) VK2735’s potential in obesity and beyond. Assuming full adherence, Novo’s CagriSema ...

Fintel reports that on April 7, 2025, HC Wainwright & Co. initiated coverage of Ionis Pharmaceuticals (LSE:0JDI) with a Buy recommendation. As of April 2, 2025, the average one-year price target ...